Clinical Report: Advances in Postoperative Inflammation Management After Cataract Surgery

Overview

Effective management of post-cataract inflammation is crucial to enhance visual recovery and patient comfort. Recent strategies emphasize minimizing topical drop burden by using intraoperative and sustained-release medications, improving adherence and outcomes.

Background

Postoperative inflammation after cataract surgery can delay visual recovery and cause discomfort. Corticosteroids and NSAIDs are key agents that inhibit prostaglandin-mediated inflammation through different mechanisms. However, traditional topical regimens face challenges such as poor patient adherence and polypharmacy. Emerging approaches focus on intraoperative injections and sustained-release drug delivery systems to overcome these limitations.

Data Highlights

Nonadherence rates with topical medications range from 30% to 80%. Intracameral moxifloxacin and intracanalicular dexamethasone inserts (Dextenza) are used to reduce drop burden. Billing codes J1096 and J1097 apply for pain-related sustained-release drugs like Dextenza and Omidria under Medicare. CPT code 68841 reimburses for intracanalicular insert placement.

Key Findings

• Corticosteroids inhibit early inflammatory pathways, while NSAIDs block downstream cyclooxygenase activity, providing synergistic anti-inflammatory effects.
• Topical drop regimens suffer from high nonadherence due to complexity, forgetfulness, and manual dexterity issues.
• Intraoperative intracameral moxifloxacin combined with sustained-release dexamethasone inserts effectively reduce inflammation and infection risk without reliance on patient drop instillation.
• Topical NSAIDs are still prescribed but with minimal dosing frequency; some surgeons consider eliminating NSAIDs in select cases.
• Glaucoma patients tolerate intracanalicular dexamethasone inserts well without increased intraocular pressure spikes, despite initial concerns.
• New sustained-release drug delivery options for glaucoma and postoperative inflammation are in development, promising further reduction in drop burden.

Clinical Implications

Incorporating intraoperative antibiotics and sustained-release steroid inserts can simplify postoperative regimens, improving patient adherence and outcomes. Clinicians should consider these options especially for patients with difficulties managing multiple topical drops or those with glaucoma. Awareness of billing codes and site-of-service considerations can facilitate access to these advanced therapies.

Conclusion

The shift toward dropless and sustained-release anti-inflammatory strategies represents a significant advancement in postoperative cataract care, enhancing patient convenience and therapeutic efficacy. Continued innovation and adoption of these modalities are expected to further optimize inflammation management.

References

1. IRIS Registry Study 2023 -- Safety of Intracanalicular Dexamethasone in Glaucoma Patients
2. Rayner Pharmaceuticals -- Omidria Product Information
3. Ocular Therapeutix -- Dextenza Clinical Data